Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A Prospective Pilot Study

Overview

The purpose of this study is to assess the efficacy and safety of a lower dose than is usually given of stereotactic radiosurgery (i.e. Gamma Knife or Linear Accelerator) for brain metastases patients receiving immunotherapy.

Description

Researchers will collect a blood sample and information from participants' medical record. Participants will receive stereotactic radiosurgery (SRS) to a dose according to the size of their metastatic brain disease. Participants will undergo normal clinical (examinations) and radiographic (brain MRI with contrast) follow-up one month after SRS and every three months after SRS for a full year.

None of the procedures participants undergo will be experimental; all are standard of care. However, the lower dose of stereotactic radiosurgery they will receive is not standard of care.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions: Brain Metastases
  • Age: Between 18 Years - 100 Years
  • Gender: Male or Female

Individuals at least 18 years of age with 1-10 solid tumor brain metastases.

Individuals with an existing autoimmune disease will not be eligible.

Updated on 20 Nov 2022 . Study ID: 1906336263

Connect with a study center near you

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center